Publications:
Chambers TJ, Droll DA, Tang Y, Liang Y, Ganesh VK,
Murthy KH, Nickells M. Yellow fever virus NS2B-NS3 protease: characterization
of charged-to-alanine mutant and revertant viruses and analysis of polyprotein-cleavage
activities.
J Gen Virol. 2005 May;86(Pt 5):1403-13.
Monath TP, Kanesa-Thasan N, Guirakhoo F, Pugachev K, Almond J, Lang J, Quentin-Millet
MJ, Barrett AD, Brinton MA, Cetron MS, Barwick RS, Chambers TJ, Halstead SB,
Roehrig JT, Kinney RM, Rico-Hesse R, Strauss JH.
Recombination and flavivirus vaccines: a commentary.
Vaccine. 2005 Apr 27;23(23):2956-8.
Chambers TJ, Fan X, Droll DA, Hembrador E, Slater T, Nickells MW, Dustin LB,
Dibisceglie AM.
Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable
during pegylated interferon therapy of chronic hepatitis C virus infection.
J Virol. 2005 Mar;79(5):3071-83.
Vlaycheva L, Nickells M, Droll DA, Chambers TJ.
Neuroblastoma cell-adapted yellow fever virus: mutagenesis of the E protein
locus involved in persistent infection and its effects on virus penetration
and spread.
J Gen Virol. 2005 Feb;86(Pt 2):413-21.
Vlaycheva L, Nickells M, Droll DA, Chambers TJ.
Yellow fever 17D virus: pseudo-revertant suppression of defective virus penetration
and spread by mutations in domains II and III of the E protein.
Virology. 2004 Sep 15;327(1):41-9.
Slater-Handshy T, Droll DA, Fan X, Di Bisceglie AM, Chambers TJ.
HCV E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects
on E2 expression and processing.
Virology. 2004 Feb 5;319(1):36-48.
Chambers TJ, Diamond MS.
Pathogenesis of flavivirus encephalitis.
Adv Virus Res. 2003;60:273-342.
Chambers TJ, Monath TP.
Preface to volume 60 the flaviviruses: pathogenesis and immunity.v Adv Virus
Res. 2003;60:xiii-xiv.
Chambers TJ, Monath TP. v Preface to the flaviviruses.v Adv Virus Res. 2003;60:ix-xi.
Nickells M, Chambers TJ.
Neuroadapted yellow fever virus 17D: determinants in the envelope protein
govern neuroinvasiveness for SCID mice.
J Virol. 2003 Nov;77(22):12232-42.
Ni J, Hembrador E, Di Bisceglie AM, Jacobson IM, Talal AH, Butera D, Rice
CM, Chambers TJ, Dustin LB. Accumulation of B lymphocytes with a naive, resting
phenotype in a subset of hepatitis C patients.
J Immunol. 2003 Mar 15;170(6):3429-39.
Chambers TJ, Liang Y, Droll DA, Schlesinger JJ, Davidson AD, Wright PJ, Jiang
X.
Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras:
biological characterization, immunogenicity, and protection against dengue
encephalitis in the mouse model.
J Virol. 2003 Mar;77(6):3655-68.
Vlaycheva LA, Chambers TJ.
Neuroblastoma cell-adapted yellow fever 17D virus: characterization of a viral
variant associated with persistent infection and decreased virus spread.
J Virol. 2002 Jun;76(12):6172-84.
Chambers TJ, Nickells M.
Neuroadapted yellow fever virus 17D: genetic and biological characterization
of a highly mouse-neurovirulent virus and its infectious molecular clone.
J Virol. 2001 Nov;75(22):10912-22.
Liu T, Chambers TJ.
Yellow fever virus encephalitis: properties of the brain-associated T-cell
response during virus clearance in normal and gamma interferon-deficient mice
and requirement for CD4+ lymphocytes.
J Virol. 2001 Mar;75(5):2107-18.
Arroyo J, Guirakhoo F, Fenner S, Zhang ZX, Monath TP, Chambers TJ.
Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese
encephalitis virus chimera vaccine (ChimeriVax-JE).
J Virol. 2001 Jan;75(2):934-42.
Droll DA, Krishna Murthy HM, Chambers TJ.
Yellow fever virus NS2B-NS3 protease: charged-to-alanine mutagenesis and deletion
analysis define regions important for protease complex formation and function.
Virology. 2000 Sep 30;275(2):335-47.
Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, Arroyo
J, Georgakopoulos K, Catalan J, Monath TP.
Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective
in nonhuman primates.
J Virol. 2000 Jun;74(12):5477-85.
Guirakhoo F, Zhang ZX, Chambers TJ, Delagrave S, Arroyo J, Barrett AD, Monath
TP. v Immunogenicity, genetic stability, and protective efficacy of a recombinant,
chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live,
attenuated vaccine candidate against Japanese encephalitis.
Virology. 1999 May 10;257(2):363-72.
Monath TP, Soike K, Levenbook I, Zhang ZX, Arroyo J, Delagrave S, Myers G,
Barrett AD, Shope RE, Ratterree M, Chambers TJ, Guirakhoo F.
Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating
the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid
and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and
protective in non-human primates.
Vaccine. 1999 Apr 9;17(15-16):1869-82.